- AbbVie is investing $195 million to expand active pharmaceutical ingredient (API) manufacturing at its North Chicago facility.
- The new facility is expected to be operational in 2027.
AbbVie has announced a $195 million investment in its North Chicago, Illinois, manufacturing site to expand domestic active pharmaceutical ingredient (API) production. The expansion is part of AbbVie’s broader plan to invest more than $10 billion in the U.S., aiming to enhance innovation and strengthen critical manufacturing capabilities.
The new facility will expand AbbVie’s chemical synthesis capabilities, supporting domestic production of current and next-generation therapies across neuroscience, immunology, and oncology. Construction is scheduled to begin in fall 2025, with operations projected to start in 2027. The expansion will complement AbbVie’s existing U.S. manufacturing footprint, which includes 11 sites and supports over 6,000 American jobs, along with thousands of additional positions at supplier organisations.
Active pharmaceutical ingredient manufacturing involves complex, multi-step processes to produce the components responsible for a medication’s therapeutic effect. The expanded North Chicago site is designed to enhance AbbVie’s capacity to produce APIs for its next-generation medicines, strengthening its U.S.-based contract manufacturing capabilities.
Robert A. Michael, chairman and CEO of AbbVie, said: “Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the U.S. to support future medical breakthroughs. This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients’ lives.”
The investment also reinforces AbbVie’s long-term commitment to Illinois, home to more than 11,000 employees involved in developing and manufacturing innovative medicines. Illinois Governor JB Pritzker added: “AbbVie’s decision to expand its manufacturing footprint in Illinois is a testament to our state’s world-class workforce, infrastructure, cutting-edge research institutions, and location that keeps businesses connected to the nation and the world.”
